Gabriel Sosne, M.D.

Education and Research

Medical School: Albert Einstein College of Medicine

Residency: Henry Ford Hospital

Fellowship: National Institute of Health

Clinical Interests: Cataract surgery, dry eye diease, diabetic eye exams, macular degeneration, inflammatory eye diseases, glaucoma, external eye diseases

Publications

• Sosne G, Ousler GW. Thymosin β4 Ophthalmic Solution for Dry Eye: A Randomized, Placebo-Controlled Phase 2 Clinical Trial Conducted Using the Controlled Adverse Environment (CAE™) Model. Expert Opinion. In revision.

• Sosne G, Kim C, Kleinman HK. Thymosin β4 Significantly Reduces the Signs of Dry Eye in a Murine Controlled Adverse Environment Model of Experimental Dry Eye. Expert Opinion. In press.

• Sosne G, Dunn SP, Kim C. Thymosin beta 4 Significantly Improve Signs and Symptoms of Severe Dry Eye in a Phase 2 Clinical Trial. CORNEA In press.

• Sosne G, Qiu P, Ousler GW 3rd, Dunn SP, Crockford D. Thymosin β4: a potential novel dry eye therapy. Ann N Y Acad Sci. 2012 Oct;1270:45-50. doi: 10.1111/j.1749-6632.2012.06682.x.

• Goldstein, AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: A Multi-Functional Regenerative Peptide Basic Properties and Clinical Applications. Expert Opin Biol Ther. 2012 Jan;12(1):37-51. Epub 2011 Nov 10.

• Qiu P, Wheater MK, Qiu Y, Sosne G. Thymosin beta 4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J. 2011 Feb 22, [Epub ahead of print]

• Dunn SP, Heidemann DG, Chow CYC, Crockford D, Turjman N, Angel J, Allan CB, and Sosne G. "Treatment of Chronic Non-Healing Neurotrophic Corneal Epithelial Defects with Thymosin 4"

• Ann N Y Acad Sci. 2010 Apr;1194:199-206. 

Dunn, SP, Heidemann DG, Chow CY, Crockford D, Turjman N,Angel, J, Allan CB, Sosne G. Arch Ophthalmol. Treatment of Chronic Nonhealing

• Neurotrophic Corneal Epithelial Defects With Thymosin Beta 4. 2010 May; 128(5):636-8. 

Sosne G, Qiu P, Goldstein AL, Wheater MK. Biological activities of thymosin beta 4 defined by active sites in short peptide sequences. FASEB J. 2010 Jul;24(7):2144-51. Epub 2010 Feb 23. 

Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal

• NFkappaB: A potential anti-inflammatory pathway. Exp Eye Res. 2007 Apr;84(4):663-9. Gabriel Sosne, M.D.